The Combinatorial Drug Discovery Program (CDDP)
Grant
Overview
Affiliation
View All
Overview
abstract
Finding new ways to use old drugs to treat cancer is one of the most effective ways to accelerate the discovery of new therapies that benefit patients with cancer. The CPRIT-funded Gulf Coast Consortium (GCC) Combinatorial Drug Discovery Program (CDDP) is a multi-institutional core facility that provides key resources to support cancer-related drug repurposing and combinatorial drug discovery research. The CDDP is a member of a network of collaborating core facilities, organized by GCC, to promote resource sharing and the elimination of wasteful duplication while providing researchers with the access to the sophisticated technologies necessary to support drug discovery research. In the last ... Read More Finding new ways to use old drugs to treat cancer is one of the most effective ways to accelerate the discovery of new therapies that benefit patients with cancer. The CPRIT-funded Gulf Coast Consortium (GCC) Combinatorial Drug Discovery Program (CDDP) is a multi-institutional core facility that provides key resources to support cancer-related drug repurposing and combinatorial drug discovery research. The CDDP is a member of a network of collaborating core facilities, organized by GCC, to promote resource sharing and the elimination of wasteful duplication while providing researchers with the access to the sophisticated technologies necessary to support drug discovery research. In the last 4 years, the CDDP has been phenomenally successful, establishing itself as a key resource for cancer-related therapeutics research in the TMC providing support to more than 60 investigators from 8 different academic institutions. Projects supported by the CDDP have led to four clinical trials that have either been activated or are in development. Research supported by the CDDP has contributed to more than $40,000,000 in new research grant awards to TMC investigators. In the next funding period the CDDP proposes not only to continue its successful program of repurposing and combinatorial drug discovery research but also to add a new component focused on the discovery of new cancer therapies based on cancer cell metabolism. This new program will support the discovery of new therapies that target the metabolic vulnerabilities of different types of cancer. It is hoped that metabolic targeted therapies will play an important role in the development of novel combinatorial therapies for drug-resistant cancers and tumors that have metastasized to specific locations such as the brain. Renewal of funding for the CDDP will support the continued development of a key cancer research facility that is contributing to the discovery of new therapies for many forms of cancer
